A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.
Glucose in blood.
A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).
Substances which lower blood glucose levels.
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511)
The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS.
A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.
A 36-amino acid pancreatic hormone that is secreted mainly by endocrine cells found at the periphery of the ISLETS OF LANGERHANS and adjacent to cells containing SOMATOSTATIN and GLUCAGON. Pancreatic polypeptide (PP), when administered peripherally, can suppress gastric secretion, gastric emptying, pancreatic enzyme secretion, and appetite. A lack of pancreatic polypeptide (PP) has been associated with OBESITY in rats and mice.
Self evaluation of whole blood glucose levels outside the clinical laboratory. A digital or battery-operated reflectance meter may be used. It has wide application in controlling unstable insulin-dependent diabetes.
Maintenance of a constant blood glucose level by perfusion or infusion with glucose or insulin. It is used for the study of metabolic rates (e.g., in glucose, lipid, amino acid metabolism) at constant glucose concentration.
Portable or implantable devices for infusion of insulin. Includes open-loop systems which may be patient-operated or controlled by a pre-set program and are designed for constant delivery of small quantities of insulin, increased during food ingestion, and closed-loop systems which deliver quantities of insulin automatically based on an electronic glucose sensor.
Insulin formulations that contain substances that retard absorption thus extending the time period of action.
Severe HYPOGLYCEMIA induced by a large dose of exogenous INSULIN resulting in a COMA or profound state of unconsciousness from which the individual cannot be aroused.
Components of medical instrumentation used for physiological evaluation of patients, that signal when a threshold value is reached.
Minor hemoglobin components of human erythrocytes designated A1a, A1b, and A1c. Hemoglobin A1c is most important since its sugar moiety is glucose covalently bound to the terminal amino acid of the beta chain. Since normal glycohemoglobin concentrations exclude marked blood glucose fluctuations over the preceding three to four weeks, the concentration of glycosylated hemoglobin A is a more reliable index of the blood sugar average over a long period of time.
A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement.
A nucleus of the middle hypothalamus, the largest cell group of the tuberal region with small-to-medium size cells.
Abnormally high BLOOD GLUCOSE level.
An inherited autosomal recessive syndrome characterized by the disorganized formation of new islets in the PANCREAS and CONGENITAL HYPERINSULINISM. It is due to focal hyperplasia of pancreatic ISLET CELLS budding off from the ductal structures and forming new islets of Langerhans. Mutations in the islet cells involve the potassium channel gene KCNJ11 or the ATP-binding cassette transporter gene ABCC8, both on CHROMOSOME 11.
A familial, nontransient HYPOGLYCEMIA with defects in negative feedback of GLUCOSE-regulated INSULIN release. Clinical phenotypes include HYPOGLYCEMIA; HYPERINSULINEMIA; SEIZURES; COMA; and often large BIRTH WEIGHT. Several sub-types exist with the most common, type 1, associated with mutations on an ATP-BINDING CASSETTE TRANSPORTERS (subfamily C, member 8).
A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.
The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.
Sulfonylurea compounds are a class of medications used in the treatment of diabetes mellitus type 2 that promote insulin secretion from pancreatic beta-cells by closing ATP-sensitive potassium channels in their membranes.
The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.
Devices for simulating the activity of the pancreas. They can be either electromechanical, consisting of a glucose sensor, computer, and insulin pump or bioartificial, consisting of isolated islets of Langerhans in an artificial membrane.
An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
Antibodies specific to INSULIN.
The act of "taking account" of an object or state of affairs. It does not imply assessment of, nor attention to the qualities or nature of the object.
Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
The use of electronic equipment to observe or record physiologic processes while the patient undergoes normal daily activities.
Insulin that has been modified to contain an ASPARTIC ACID instead of a PROLINE at position 38 of the B-chain.
An intermediate-acting INSULIN preparation with onset time of 2 hours and duration of 24 hours. It is produced by crystallizing ZINC-insulin-PROTAMINES at neutral pH 7. Thus it is called neutral protamine Hagedorn for inventor Hans Christian Hagedorn.
A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
Regular insulin preparations that contain the SUS SCROFA insulin peptide sequence.
Biosynthesis of GLUCOSE from nonhexose or non-carbohydrate precursors, such as LACTATE; PYRUVATE; ALANINE; and GLYCEROL.
BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
The ENTERIC NERVOUS SYSTEM; PARASYMPATHETIC NERVOUS SYSTEM; and SYMPATHETIC NERVOUS SYSTEM taken together. Generally speaking, the autonomic nervous system regulates the internal environment during both peaceful activity and physical or emotional stress. Autonomic activity is controlled and integrated by the CENTRAL NERVOUS SYSTEM, especially the HYPOTHALAMUS and the SOLITARY NUCLEUS, which receive information relayed from VISCERAL AFFERENTS.
The administration of liquid medication or nutrients under the skin, usually over minutes or hours.
A 191-amino acid polypeptide hormone secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR), also known as GH or somatotropin. Synthetic growth hormone, termed somatropin, has replaced the natural form in therapeutic usage such as treatment of dwarfism in children with growth hormone deficiency.
A benign tumor of the pancreatic ISLET CELLS. Usually it involves the INSULIN-producing PANCREATIC BETA CELLS, as in INSULINOMA, resulting in HYPERINSULINISM.
A degenerative disease of the AUTONOMIC NERVOUS SYSTEM that is characterized by idiopathic ORTHOSTATIC HYPOTENSION and a greatly reduced level of CATECHOLAMINES. No other neurological deficits are present.
The processes whereby the internal environment of an organism tends to remain balanced and stable.
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
Gastrointestinal symptoms resulting from an absent or nonfunctioning pylorus.
Abstaining from all food.
Surgical removal of the pancreas. (Dorland, 28th ed)
FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form.
An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP).
An infant during the first month after birth.
ATP-BINDING CASSETTE PROTEINS that are highly conserved and widely expressed in nature. They form an integral part of the ATP-sensitive potassium channel complex which has two intracellular nucleotide folds that bind to sulfonylureas and their analogs.
Disorders characterized by physical or psychological symptoms that are not real, genuine, or natural.
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN.
Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.
Elements of limited time intervals, contributing to particular results or situations.

Inactivation of the winged helix transcription factor HNF3alpha affects glucose homeostasis and islet glucagon gene expression in vivo. (1/2319)

Mice homozygous for a null mutation in the winged helix transcription factor HNF3alpha showed severe postnatal growth retardation followed by death between P2 and P12. Homozygous mutant mice were hypoglycemic despite unchanged expression of HNF3 target genes involved in hepatic gluconeogenesis. Whereas insulin and corticosteroid levels were altered as expected, plasma glucagon was reduced markedly in the mutant animals despite the hypoglycemia that should be expected to increase glucagon levels. This correlated with a 70% reduction in pancreatic proglucagon gene expression. We also showed that HNF3alpha could bind to and transactivate the proglucagon gene promoter. These observations invoke a central role for HNF3alpha in the regulatory control of islet genes essential for glucose homeostasis in vivo.  (+info)

Hypoglycemia and torpor in Siberian hamsters. (2/2319)

We tested whether reduced blood glucose concentrations are necessary and sufficient for initiation of torpor in Siberian hamsters. During spontaneous torpor bouts, body temperature (Tb) decreases from the euthermic value of 37 to <31 degrees C. Among hamsters that displayed torpor during maintenance in a short-day length (10 h light/day) at an air temperature of 15 degrees C, blood glucose concentrations decreased significantly by 28% as Tb fell from 37 to <31 degrees C and increased during rewarming so that by the time Tb first was >36 degrees C, glucose concentrations had returned to the value preceding torpor. Hamsters did not display torpor when maintained in a long-day length (16 h light/day) and injected with a range of insulin doses (1-50 U/kg body mass), some of which resulted in sustained, pronounced hypoglycemia. We conclude that changes in blood glucose concentrations may be a consequence rather than a cause of the torpid state and question whether induction of torpor by 2-deoxy-D-glucose is due to its general glucoprivic actions.  (+info)

Time-dependent and tissue-specific effects of circulating glucose on fetal ovine glucose transporters. (3/2319)

To determine the cellular adaptations to fetal hyperglycemia and hypoglycemia, we examined the time-dependent effects on basal (GLUT-1 and GLUT-3) and insulin-responsive (GLUT-4) glucose transporter proteins by quantitative Western blot analysis in fetal ovine insulin-insensitive (brain and liver) and insulin-sensitive (myocardium, skeletal muscle, and adipose) tissues. Maternal glucose infusions causing fetal hyperglycemia resulted in a transient 30% increase in brain GLUT-1 but not GLUT-3 levels and a decline in liver and adipose GLUT-1 and myocardial and skeletal muscle GLUT-1 and GLUT-4 levels compared with gestational age-matched controls. Maternal insulin infusions leading to fetal hypoglycemia caused a decline in brain GLUT-3, an increase in brain GLUT-1, and a subsequent decline in liver GLUT-1, with no significant change in insulin-sensitive myocardium, skeletal muscle, and adipose tissue GLUT-1 or GLUT-4 concentrations, compared with gestational age-matched sham controls. We conclude that fetal glucose transporters are subject to a time-dependent and tissue- and isoform-specific differential regulation in response to altered circulating glucose and/or insulin concentrations. These cellular adaptations in GLUT-1 (and GLUT-3) are geared toward protecting the conceptus from perturbations in substrate availability, and the adaptations in GLUT-4 are geared toward development of fetal insulin resistance.  (+info)

Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. (4/2319)

BACKGROUND: Genetic defects are being increasingly recognized in the etiology of primary cardiomyopathy (CM). Very-long-chain acyl-CoA dehydrogenase (VLCAD) catalyzes the first step in the beta-oxidation spiral of fatty acid metabolism, the crucial pathway for cardiac energy production. METHODS AND RESULTS: We studied 37 patients with CM, nonketotic hypoglycemia and hepatic dysfunction, skeletal myopathy, or sudden death in infancy with hepatic steatosis, features suggestive of fatty acid oxidation disorders. Single-stranded conformational variance was used to screen genomic DNA. DNA sequencing and mutational analysis revealed 21 different mutations on the VLCAD gene in 18 patients. Of the mutations, 80% were associated with CM. Severe CM in infancy was recognized in most patients (67%) at presentation. Hepatic dysfunction was common (33%). RNA blot analysis and VLCAD enzyme assays showed a severe reduction in VLCAD mRNA in patients with frame-shift or splice-site mutations and absent or severe reduction in enzyme activity in all. CONCLUSIONS: Infantile CM is the most common clinical phenotype of VLCAD deficiency. Mutations in the human VLCAD gene are heterogeneous. Although mortality at presentation is high, both the metabolic disorder and cardiomyopathy are reversible.  (+info)

Chronic hypoglycemia and diabetes impair counterregulation induced by localized 2-deoxy-glucose perfusion of the ventromedial hypothalamus in rats. (5/2319)

Previous studies have demonstrated that the ventromedial hypothalamus (VMH) plays a critical role in sensing and responding to systemic hypoglycemia. To evaluate the mechanisms of defective counterregulation caused by iatrogenic hypoglycemia and diabetes per se, we delivered 2-deoxy-glucose (2-DG) via microdialysis into the VMH to produce localized cellular glucopenia in the absence of systemic hypoglycemia. Three groups of awake chronically catheterized rats were studied: 1) nondiabetic (with a mean daily glucose [MDG] of 6.9 mmol/l) BB control rats (n = 5); 2) chronically hypoglycemic nondiabetic (3-4 weeks, with an MDG of 2.7 mmol/l) BB rats (n = 5); and 3) moderately hyperglycemic insulin-treated diabetic (with an MDG of 12.4 mmol/l) BB rats (n = 8). In hypoglycemic rats, both glucagon and catecholamine responses to VMH glucopenia were markedly (77-93%) suppressed. In diabetic rats, VMH 2-DG perfusion was totally ineffective in stimulating glucagon release. The epinephrine response, but not the norepinephrine response, was also diminished by 38% in the diabetic group. We conclude that impaired counterregulation after chronic hypoglycemia may result from alterations of the VMH or its efferent pathways. In diabetes, the capacity of VMH glucopenia to activate the sympathoadrenal system is only modestly diminished; however, the communication between the VMH and the alpha-cell is totally interrupted.  (+info)

The neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary Cushing's disease. (6/2319)

The neuroendocrine protein 7B2 has been implicated in activation of prohormone convertase 2 (PC2), an important neuroendocrine precursor processing endoprotease. To test this hypothesis, we created a null mutation in 7B2 employing a novel transposon-facilitated technique and compared the phenotypes of 7B2 and PC2 nulls. 7B2 null mice have no demonstrable PC2 activity, are deficient in processing islet hormones, and display hypoglycemia, hyperproinsulinemia, and hypoglucagonemia. In contrast to the PC2 null phenotype, these mice show markedly elevated circulating ACTH and corticosterone levels, with adrenocortical expansion. They die before 9 weeks of severe Cushing's syndrome arising from pituitary intermediate lobe ACTH hypersecretion. We conclude that 7B2 is indeed required for activation of PC2 in vivo but has additional important functions in regulating pituitary hormone secretion.  (+info)

Biopsychobehavioral model of risk of severe hypoglycemia. Self-management behaviors. (7/2319)

OBJECTIVE: To identify self-management antecedents of low blood glucose (BG) (< 3.9 mmol/l) that might be easily recognized, treated, or avoided altogether. RESEARCH DESIGN AND METHODS: Ninety-three adults with type 1 diabetes (age, 35.8 +/- 8 years [mean +/- SD]; duration of diabetes, 17.0 +/- 11 years; daily insulin dose, 0.58 +/- 0.18 U/kg; and HbAlc, 8.6 +/- 1.8%) were recruited to participate in the study. Of the 93 subjects, 42 had a history of severe hypoglycemia (SH), defined as two or more hypoglycemic episodes in the preceding 12 months, and 51 subjects had no history of SH (No-SH) in the same time period. Before each of 70 BG measurements obtained over a 3-week period, subjects used a handheld computer to record whether their most recent insulin, food, and exercise was more than, less than, or the same as usual. Associations among self-management behaviors preceding BG readings < 3.9 mmol/l versus those preceding BG readings of 5.6-7.8 mmol/l were determined using chi 2 tests, analyses of variance, and logistic regression analyses. RESULTS: Analysis of 6,425 self-management/self-monitoring of BG events revealed that the usual amounts of insulin, food, and exercise preceded the events 58.3% of the time. No significant differences were observed for changes in insulin before readings of BG < 3.9 mmol/l versus 7.8 < BG > 5.6 mmol/l, but significantly less food (P < 0.01) was eaten and more exercise (P < 0.001) was performed before the low BG measurement. No interactions between SH and No-SH groups and management behaviors were observed. However, each of the three management variables entered significantly in a logistic model that predicted 61% of all readings of BG < 3.9 mmol/l. CONCLUSIONS: Subjects with a history of SH did not report managing their diabetes differently from those with no such history. Specifically, when low BG occurred, the preceding management behaviors, although predictive of low BG, were not different in SH and No-SH subjects. Overall, self-management behaviors did not distinguish SH from No-SH subjects. Thus, even though it might be beneficial for all patients to review their food and exercise management decisions to reduce their frequency of low BG, an educational intervention whose content stresses insulin, food, and exercise would be unlikely by itself to be sufficient to reduce the frequency of SH.  (+info)

Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. A double-blind randomized prospective trial. The Canadian Lispro Study Group. (8/2319)

OBJECTIVE: To compare human ultralente (UL) insulin with human NPH insulin as basal insulin replacement in patients who use insulin lispro before meals. RESEARCH DESIGN AND METHODS: There were 178 patients with type 1 diabetes who were randomized to receive either human NPH or UL insulin once daily at bedtime in a 1-year double-blind clinical study. Eight-point blood glucose profiles were collected once monthly in the first 4 months, then every 2 months for the remainder of the study. Patients were also asked to perform premeal blood glucose measurements every day throughout the study. If before-supper blood glucose levels consistently exceeded 8 mmol/l despite optimal postprandial control with the lunch dose of insulin lispro, a second dose of basal insulin before breakfast was administered. RESULTS: For the group as a whole, insulin doses before meals and basal insulin doses were similar at baseline. At study's end, meal doses remained the same (30 +/- 1 U/day for UL., 29 +/- 1 U/day for NPH), while basal requirements were somewhat higher for the UL group than the NPH group: 30 +/- 1 U/day vs. 26 +/- 1 U/day, respectively (P < 0.05). The rates of severe hypoglycemia were similar for patients on NPH (0.05 +/- 0.03 per patient every 30 days) and for UL (0.07 +/- 0.04 per patient every 30 days) insulin. There was no significant difference for glycemic control between the NPH and UL groups overall (HbAlc at the end of the study: 7.6 +/- 0.1 vs. 7.7 +/- 0.1%, respectively), and by study's end a similar number of patients in the NPH and the UL groups needed to be switched to twice daily basal insulin (21 and 24%, respectively). Patients requiring twice-daily injections of basal insulin had a longer duration of diabetes (17.8 +/- 1.5 vs. 14.0 +/- 0.8 years, P < 0.05) and a highest baseline HbAlc (8.6 +/- 0.1 vs. 8.0 +/- 0.1%, P < 0.002) and were significantly older (38 +/- 2 vs. 34 +/- 1 years, P < 0.007). Patients who were switched to twice-daily NPH insulin had lower HbAlc levels at study's end compared with those switched to twice-daily UL insulin (7.7 +/- 0.2 vs. 8.2 +/- 0.3%), but this difference was not statistically significant. Distribution of hypoglycemia across the day was also similar in both groups. CONCLUSIONS: UL or NPH insulin, when used as the basal insulin for multiple injection regimens, results in similar glycemic control in patients using insulin lispro before meals. However, in patients who require a second injection of basal insulin, NPH insulin appears to provide lower prebreakfast and prelunch glucose levels compared with UL insulin.  (+info)

Hypoglycemia is a medical condition characterized by an abnormally low level of glucose (sugar) in the blood. Generally, hypoglycemia is defined as a blood glucose level below 70 mg/dL (3.9 mmol/L), although symptoms may not occur until the blood sugar level falls below 55 mg/dL (3.0 mmol/L).

Hypoglycemia can occur in people with diabetes who are taking insulin or medications that increase insulin production, as well as those with certain medical conditions such as hormone deficiencies, severe liver illnesses, or disorders of the adrenal glands. Symptoms of hypoglycemia include sweating, shaking, confusion, rapid heartbeat, and in severe cases, loss of consciousness or seizures.

Hypoglycemia is typically treated by consuming fast-acting carbohydrates such as fruit juice, candy, or glucose tablets to rapidly raise blood sugar levels. If left untreated, hypoglycemia can lead to serious complications, including brain damage and even death.

Blood glucose, also known as blood sugar, is the concentration of glucose in the blood. Glucose is a simple sugar that serves as the main source of energy for the body's cells. It is carried to each cell through the bloodstream and is absorbed into the cells with the help of insulin, a hormone produced by the pancreas.

The normal range for blood glucose levels in humans is typically between 70 and 130 milligrams per deciliter (mg/dL) when fasting, and less than 180 mg/dL after meals. Levels that are consistently higher than this may indicate diabetes or other metabolic disorders.

Blood glucose levels can be measured through a variety of methods, including fingerstick blood tests, continuous glucose monitoring systems, and laboratory tests. Regular monitoring of blood glucose levels is important for people with diabetes to help manage their condition and prevent complications.

Insulin is a hormone produced by the beta cells of the pancreatic islets, primarily in response to elevated levels of glucose in the circulating blood. It plays a crucial role in regulating blood glucose levels and facilitating the uptake and utilization of glucose by peripheral tissues, such as muscle and adipose tissue, for energy production and storage. Insulin also inhibits glucose production in the liver and promotes the storage of excess glucose as glycogen or triglycerides.

Deficiency in insulin secretion or action leads to impaired glucose regulation and can result in conditions such as diabetes mellitus, characterized by chronic hyperglycemia and associated complications. Exogenous insulin is used as a replacement therapy in individuals with diabetes to help manage their blood glucose levels and prevent long-term complications.

Hypoglycemic agents are a class of medications that are used to lower blood glucose levels in the treatment of diabetes mellitus. These medications work by increasing insulin sensitivity, stimulating insulin release from the pancreas, or inhibiting glucose production in the liver. Examples of hypoglycemic agents include sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists. It's important to note that the term "hypoglycemic" refers to a condition of abnormally low blood glucose levels, but in this context, the term is used to describe agents that are used to treat high blood glucose levels (hyperglycemia) associated with diabetes.

Diabetes Mellitus, Type 1 is a chronic autoimmune disease characterized by the destruction of insulin-producing beta cells in the pancreas, leading to an absolute deficiency of insulin. This results in an inability to regulate blood glucose levels, causing hyperglycemia (high blood sugar). Type 1 diabetes typically presents in childhood or early adulthood, although it can develop at any age. It is usually managed with regular insulin injections or the use of an insulin pump, along with monitoring of blood glucose levels and adjustments to diet and physical activity. Uncontrolled type 1 diabetes can lead to serious complications such as kidney damage, nerve damage, blindness, and cardiovascular disease.

Glucagon is a hormone produced by the alpha cells of the pancreas. Its main function is to regulate glucose levels in the blood by stimulating the liver to convert stored glycogen into glucose, which can then be released into the bloodstream. This process helps to raise blood sugar levels when they are too low, such as during hypoglycemia.

Glucagon is a 29-amino acid polypeptide that is derived from the preproglucagon protein. It works by binding to glucagon receptors on liver cells, which triggers a series of intracellular signaling events that lead to the activation of enzymes involved in glycogen breakdown.

In addition to its role in glucose regulation, glucagon has also been shown to have other physiological effects, such as promoting lipolysis (the breakdown of fat) and inhibiting gastric acid secretion. Glucagon is often used clinically in the treatment of hypoglycemia, as well as in diagnostic tests to assess pancreatic function.

Epinephrine, also known as adrenaline, is a hormone and a neurotransmitter that is produced in the body. It is released by the adrenal glands in response to stress or excitement, and it prepares the body for the "fight or flight" response. Epinephrine works by binding to specific receptors in the body, which causes a variety of physiological effects, including increased heart rate and blood pressure, improved muscle strength and alertness, and narrowing of the blood vessels in the skin and intestines. It is also used as a medication to treat various medical conditions, such as anaphylaxis (a severe allergic reaction), cardiac arrest, and low blood pressure.

Hyperinsulinism is a medical condition characterized by an excess production and release of insulin from the pancreas. Insulin is a hormone that helps regulate blood sugar levels by allowing cells in the body to take in sugar (glucose) for energy or storage. In hyperinsulinism, the increased insulin levels can cause low blood sugar (hypoglycemia), which can lead to symptoms such as sweating, shaking, confusion, and in severe cases, seizures or loss of consciousness.

There are several types of hyperinsulinism, including congenital forms that are present at birth and acquired forms that develop later in life. Congenital hyperinsulinism is often caused by genetic mutations that affect the way insulin is produced or released from the pancreas. Acquired hyperinsulinism can be caused by factors such as certain medications, hormonal disorders, or tumors of the pancreas.

Treatment for hyperinsulinism depends on the underlying cause and severity of the condition. Treatment options may include dietary changes, medication to reduce insulin secretion, or surgery to remove part or all of the pancreas.

Pancreatic polypeptide (PP) is a hormone that is produced and released by the pancreas, specifically by the F cells located in the islets of Langerhans. It is a small protein consisting of 36 amino acids, and it plays a role in regulating digestive functions, particularly by inhibiting pancreatic enzyme secretion and gastric acid secretion.

PP is released into the bloodstream in response to food intake, especially when nutrients such as proteins and fats are present in the stomach. It acts on the brain to produce a feeling of fullness or satiety, which helps to regulate appetite and eating behavior. Additionally, PP has been shown to have effects on glucose metabolism, insulin secretion, and energy balance.

In recent years, there has been growing interest in the potential therapeutic uses of PP for a variety of conditions, including obesity, diabetes, and gastrointestinal disorders. However, more research is needed to fully understand its mechanisms of action and clinical applications.

Blood glucose self-monitoring is the regular measurement of blood glucose levels performed by individuals with diabetes to manage their condition. This process involves using a portable device, such as a glucometer or continuous glucose monitor (CGM), to measure the amount of glucose present in a small sample of blood, usually obtained through a fingerstick.

The primary purpose of self-monitoring is to help individuals with diabetes understand how various factors, such as food intake, physical activity, medication, and stress, affect their blood glucose levels. By tracking these patterns, they can make informed decisions about adjusting their diet, exercise, or medication regimens to maintain optimal glycemic control and reduce the risk of long-term complications associated with diabetes.

Self-monitoring is an essential component of diabetes self-management and education, enabling individuals to take an active role in their healthcare. Regular monitoring also allows healthcare professionals to assess a patient's adherence to their treatment plan and make necessary adjustments based on the data collected.

The glucose clamp technique is a method used in medical research, particularly in the study of glucose metabolism and insulin action. It's a controlled procedure that aims to maintain a steady state of plasma glucose concentration in an individual for a specific period.

In this technique, a continuous infusion of glucose is administered intravenously at a variable rate to balance the amount of glucose being removed from the circulation (for example, by insulin-stimulated uptake in muscle and fat tissue). This creates a "clamp" of stable plasma glucose concentration.

The rate of glucose infusion is adjusted according to frequent measurements of blood glucose levels, typically every 5 to 10 minutes, to keep the glucose level constant. The glucose clamp technique allows researchers to study how different factors, such as various doses of insulin or other drugs, affect glucose metabolism under standardized conditions.

There are two primary types of glucose clamps: the hyperglycemic clamp and the euglycemic clamp. The former aims to raise and maintain plasma glucose at a higher-than-normal level, while the latter maintains plasma glucose at a normal, euglycemic level.

An Insulin Infusion System, also known as an insulin pump, is a medical device designed to deliver insulin in a continuous and controlled manner. It consists of a small computerized device that is worn outside the body, connected to a thin tube called a cannula which is inserted under the skin using a needle. The cannula is typically changed every 2-3 days.

The system allows for the programming of basal rates (background insulin), as well as bolus doses (additional insulin given at mealtimes or to correct high blood glucose levels). The user has the ability to customize these settings based on their individual needs, which can be particularly useful for people with type 1 diabetes who require multiple daily injections of insulin.

Insulin infusion systems are designed to mimic the normal physiological release of insulin from the pancreas more closely than traditional injection methods, and they have been shown to improve glycemic control and quality of life for some people with diabetes. However, they also require a significant amount of user education and training to ensure safe and effective use.

Long-acting insulin is a type of insulin therapy used in the management of diabetes mellitus. It refers to a class of insulin products that have a prolonged duration of action, typically lasting between 18 and 24 hours or even up to 36 hours. This allows for once-or twice-daily dosing, providing a steady basal level of insulin to help control blood glucose levels throughout the day and night.

Examples of long-acting insulins include:

1. Insulin Glargine (e.g., Lantus, Toujeo, Basaglar)
2. Insulin Detemir (e.g., Levemir)
3. Insulin Degludec (e.g., Tresiba)

These insulins are designed to have a smooth and consistent release profile, minimizing the risk of hypoglycemia (low blood sugar) compared to older intermediate-acting insulins like NPH or lente insulin. However, individual responses to insulin may vary, and proper dosing, timing, and monitoring are essential for safe and effective use. Always consult with a healthcare professional for personalized advice on insulin therapy.

An Insulin Coma is not a formal medical term, but it has been used in the past to describe a deliberate medical procedure known as Insulin Shock Therapy. This was a treatment for mental illness that involved administering large doses of insulin to induce hypoglycemia (low blood sugar), which could lead to a coma.

The idea behind this therapy, which was popular in the mid-20th century, was that the induced coma and subsequent recovery could have therapeutic effects on the brain and help alleviate symptoms of mental illnesses like schizophrenia. However, this treatment fell out of favor due to its significant risks and the development of more effective and safer treatments.

It's important to note that in current medical practice, inducing a coma with insulin is not a standard or recommended procedure due to the potential for severe harm, including brain damage and death.

Clinical alarms are audible or visual signals that are generated by medical devices to alert healthcare providers about a patient's physiological status or the malfunction of a device. These alarms can be triggered when a patient's vital signs, such as heart rate, blood pressure, oxygen saturation, or respiratory rate, fall outside of predetermined parameters or when there is a problem with the medical equipment itself.

The purpose of clinical alarms is to provide timely and accurate information to healthcare providers so that they can take appropriate action to address the patient's needs. However, the high volume of alarms that are generated in modern healthcare settings has become a significant safety concern. Many alarms are false or clinically insignificant, leading to alarm fatigue among healthcare providers and an increased risk of missed alarms and adverse events.

Therefore, it is essential to implement strategies to optimize clinical alarm management, such as customizing alarm parameters for individual patients, reducing unnecessary alarms, improving alarm documentation and communication, and providing education and training to healthcare providers on alarm management best practices.

Glycosylated Hemoglobin A, also known as Hemoglobin A1c or HbA1c, is a form of hemoglobin that is bound to glucose. It is formed in a non-enzymatic glycation reaction with glucose in the blood. The amount of this hemoglobin present in the blood is proportional to the average plasma glucose concentration over the previous 8-12 weeks, making it a useful indicator for monitoring long-term blood glucose control in people with diabetes mellitus.

In other words, HbA1c reflects the integrated effects of glucose regulation over time and is an important clinical marker for assessing glycemic control and risk of diabetic complications. The normal range for HbA1c in individuals without diabetes is typically less than 5.7%, while a value greater than 6.5% is indicative of diabetes.

Glucose is a simple monosaccharide (or single sugar) that serves as the primary source of energy for living organisms. It's a fundamental molecule in biology, often referred to as "dextrose" or "grape sugar." Glucose has the molecular formula C6H12O6 and is vital to the functioning of cells, especially those in the brain and nervous system.

In the body, glucose is derived from the digestion of carbohydrates in food, and it's transported around the body via the bloodstream to cells where it can be used for energy. Cells convert glucose into a usable form through a process called cellular respiration, which involves a series of metabolic reactions that generate adenosine triphosphate (ATP)—the main currency of energy in cells.

Glucose is also stored in the liver and muscles as glycogen, a polysaccharide (multiple sugar) that can be broken down back into glucose when needed for energy between meals or during physical activity. Maintaining appropriate blood glucose levels is crucial for overall health, and imbalances can lead to conditions such as diabetes mellitus.

The ventromedial hypothalamic nucleus (VMN) is a collection of neurons located in the ventromedial region of the hypothalamus, a part of the brain that regulates various autonomic and endocrine functions. The VMN plays an essential role in regulating several physiological processes, including feeding behavior, energy balance, and glucose homeostasis. It contains neurons that are sensitive to changes in nutrient status, such as leptin and insulin levels, and helps to integrate this information with other signals to modulate food intake and energy expenditure. Additionally, the VMN has been implicated in the regulation of various emotional and motivational states, including anxiety, fear, and reward processing.

Hyperglycemia is a medical term that refers to an abnormally high level of glucose (sugar) in the blood. Fasting hyperglycemia is defined as a fasting blood glucose level greater than or equal to 126 mg/dL (milligrams per deciliter) on two separate occasions. Alternatively, a random blood glucose level greater than or equal to 200 mg/dL in combination with symptoms of hyperglycemia (such as increased thirst, frequent urination, blurred vision, and fatigue) can also indicate hyperglycemia.

Hyperglycemia is often associated with diabetes mellitus, a chronic metabolic disorder characterized by high blood glucose levels due to insulin resistance or insufficient insulin production. However, hyperglycemia can also occur in other conditions such as stress, surgery, infection, certain medications, and hormonal imbalances.

Prolonged or untreated hyperglycemia can lead to serious complications such as diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), and long-term damage to various organs such as the eyes, kidneys, nerves, and blood vessels. Therefore, it is essential to monitor blood glucose levels regularly and maintain them within normal ranges through proper diet, exercise, medication, and lifestyle modifications.

Nesidioblastosis is a very rare condition that affects the pancreas, a gland located behind the stomach that produces hormones and enzymes to help with digestion. In nesidioblastosis, there is an abnormal increase in the number of cells called beta cells in the pancreas that produce insulin, a hormone that regulates blood sugar levels. This can lead to persistent hyperinsulinemia (high levels of insulin in the blood) and hypoglycemia (low blood sugar levels), even when the person has not eaten for several hours.

The term "nesidioblastosis" comes from the Greek words "nesis," meaning island, and "blastos," meaning germ or bud. It refers to the abnormal formation of islets of Langerhans, which are clusters of hormone-producing cells in the pancreas. In nesidioblastosis, there is an overgrowth of beta cells within these islets, leading to excessive insulin production and secretion.

Nesidioblastosis can be congenital (present at birth) or acquired later in life. It is often diagnosed in infants and young children but can also occur in adults. The symptoms of nesidioblastosis include sweating, tremors, irritability, seizures, and loss of consciousness due to low blood sugar levels. Treatment typically involves medication to control insulin secretion, dietary modifications, and, in some cases, surgery to remove part or all of the pancreas.

Congenital hyperinsulinism is a medical condition that is present at birth and characterized by the excessive production and release of insulin from the beta cells of the pancreas. Insulin is a hormone that regulates blood sugar levels, and an overproduction of it can lead to low blood sugar (hypoglycemia).

There are two main types of congenital hyperinsulinism: diffuse and focal. Diffuse hyperinsulinism affects the entire pancreas, while focal hyperinsulinism affects only a small part of it. The condition can be caused by genetic mutations that affect the way insulin is produced or released from the beta cells.

Symptoms of congenital hyperinsulinism may include hypoglycemia, which can cause symptoms such as seizures, lethargy, irritability, and poor feeding. If left untreated, severe hypoglycemia can lead to brain damage or even death. Treatment for congenital hyperinsulinism typically involves medication to control blood sugar levels, as well as dietary modifications and, in some cases, surgery to remove the affected part of the pancreas.

Insulinoma is a rare type of neuroendocrine tumor that originates from the beta cells of the pancreatic islets (islets of Langerhans). These tumors produce and secrete excessive amounts of insulin, leading to hypoglycemia (low blood sugar levels) even when the person hasn't eaten for a while. Insulinomas are typically slow-growing and benign (noncancerous), but about 10% of them can be malignant (cancerous) and may spread to other parts of the body. Common symptoms include sweating, confusion, dizziness, and weakness due to low blood sugar levels. The diagnosis is often confirmed through imaging tests like CT scans or MRI, and measuring insulin and C-peptide levels in the blood during a fasting test. Treatment usually involves surgical removal of the tumor.

C-peptide is a byproduct that is produced when the hormone insulin is generated in the body. Insulin is a hormone that helps regulate blood sugar levels, and it is produced in the pancreas by specialized cells called beta cells. When these cells produce insulin, they also generate C-peptide as a part of the same process.

C-peptide is often used as a marker to measure the body's insulin production. By measuring C-peptide levels in the blood, healthcare providers can get an idea of how much insulin the body is producing on its own. This can be helpful in diagnosing and monitoring conditions such as diabetes, which is characterized by impaired insulin production or function.

It's worth noting that C-peptide is not typically used as a treatment for any medical conditions. Instead, it is primarily used as a diagnostic tool to help healthcare providers better understand their patients' health status and make informed treatment decisions.

Sulfonylurea compounds are a group of medications used in the management of type 2 diabetes. They work by stimulating the release of insulin from the pancreas, thereby lowering blood glucose levels. These compounds bind to specific receptors on the beta cells of the pancreas, which triggers the release of insulin.

Examples of sulfonylurea compounds include glipizide, glyburide, and glimepiride. It's important to note that these medications can cause hypoglycemia (low blood sugar) if not properly monitored and dosed. They are often used in combination with other medications, such as metformin, to achieve optimal blood glucose control.

As with any medication, sulfonylurea compounds should be taken under the supervision of a healthcare provider, who can monitor their effectiveness and potential side effects.

Hydrocortisone is a synthetic glucocorticoid, which is a class of steroid hormones. It is identical to the naturally occurring cortisol, a hormone produced by the adrenal gland that helps regulate metabolism and helps your body respond to stress. Hydrocortisone has anti-inflammatory effects and is used to treat various inflammatory conditions such as allergies, skin disorders, and autoimmune diseases. It works by suppressing the immune system's response to reduce swelling, redness, itching, and other symptoms caused by inflammation.

Hydrocortisone is available in different forms, including oral tablets, topical creams, lotions, gels, and ointments, as well as injectable solutions. The specific use and dosage depend on the condition being treated and the individual patient's medical history and current health status.

As with any medication, hydrocortisone can have side effects, especially when used in high doses or for extended periods. Common side effects include increased appetite, weight gain, mood changes, insomnia, and skin thinning. Long-term use of hydrocortisone may also increase the risk of developing osteoporosis, diabetes, cataracts, and other health problems. Therefore, it is essential to follow your healthcare provider's instructions carefully when using this medication.

Diabetes Mellitus, Type 2 is a metabolic disorder characterized by high blood glucose (or sugar) levels resulting from the body's inability to produce sufficient amounts of insulin or effectively use the insulin it produces. This form of diabetes usually develops gradually over several years and is often associated with older age, obesity, physical inactivity, family history of diabetes, and certain ethnicities.

In Type 2 diabetes, the body's cells become resistant to insulin, meaning they don't respond properly to the hormone. As a result, the pancreas produces more insulin to help glucose enter the cells. Over time, the pancreas can't keep up with the increased demand, leading to high blood glucose levels and diabetes.

Type 2 diabetes is managed through lifestyle modifications such as weight loss, regular exercise, and a healthy diet. Medications, including insulin therapy, may also be necessary to control blood glucose levels and prevent long-term complications associated with the disease, such as heart disease, nerve damage, kidney damage, and vision loss.

Norepinephrine, also known as noradrenaline, is a neurotransmitter and a hormone that is primarily produced in the adrenal glands and is released into the bloodstream in response to stress or physical activity. It plays a crucial role in the "fight-or-flight" response by preparing the body for action through increasing heart rate, blood pressure, respiratory rate, and glucose availability.

As a neurotransmitter, norepinephrine is involved in regulating various functions of the nervous system, including attention, perception, motivation, and arousal. It also plays a role in modulating pain perception and responding to stressful or emotional situations.

In medical settings, norepinephrine is used as a vasopressor medication to treat hypotension (low blood pressure) that can occur during septic shock, anesthesia, or other critical illnesses. It works by constricting blood vessels and increasing heart rate, which helps to improve blood pressure and perfusion of vital organs.

An artificial pancreas is not a literal organ like a biological pancreas. Instead, it refers to a closed-loop system that integrates a continuous glucose monitor (CGM) with an insulin pump to automatically regulate blood glucose levels in individuals with diabetes. This system mimics the functions of a healthy pancreas by constantly monitoring blood sugar levels and delivering the appropriate amount of insulin as needed, without requiring manual input from the user.

The artificial pancreas is still an area of active research and development, and various prototypes and systems are being tested in clinical trials to improve their accuracy, safety, and effectiveness. The ultimate goal of developing an artificial pancreas is to provide a more effective and convenient way to manage diabetes, reduce the risk of complications, and improve quality of life for people with diabetes.

Glipizide is an oral anti-diabetic medication belonging to the sulfonylurea class. It is used in the management of type 2 diabetes mellitus, by stimulating the release of insulin from the pancreas and reducing glucose production in the liver. Glipizide works by binding to specific receptors on the beta cells of the pancreas, leading to an increase in intracellular calcium levels and ultimately resulting in insulin secretion.

The medical definition of Glipizide is: "A second-generation sulfonylurea used in the treatment of type 2 diabetes mellitus. It acts by binding to specific receptors on the beta cells of the pancreas, leading to an increase in intracellular calcium levels and insulin secretion."

It is important to note that Glipizide should be used with caution in patients with impaired kidney or liver function, as well as those who are at risk for hypoglycemia. Regular monitoring of blood glucose levels is necessary during treatment with Glipizide to ensure safe and effective use.

Insulin antibodies are proteins produced by the immune system that recognize and bind to insulin. They are typically formed in response to an exposure to exogenous insulin, such as in people with diabetes who use insulin therapy. In some cases, the presence of insulin antibodies can affect insulin absorption, distribution, metabolism, and elimination, leading to variable insulin requirements, reduced glycemic control, and potentially an increased risk of hypoglycemia or hyperglycemia. However, not all individuals with insulin antibodies experience clinical consequences, and the significance of their presence can vary between individuals.

In a medical context, awareness generally refers to the state of being conscious or cognizant of something. This can include being aware of one's own thoughts, feelings, and experiences, as well as being aware of external events or sensations.

For example, a person who is awake and alert is said to have full awareness, while someone who is in a coma or under general anesthesia may be described as having reduced or absent awareness. Similarly, a person with dementia or Alzheimer's disease may have impaired awareness of their surroundings or of their own memory and cognitive abilities.

In some cases, awareness may also refer to the process of becoming informed or educated about a particular health condition or medical treatment. For example, a patient may be encouraged to increase their awareness of heart disease risk factors or of the potential side effects of a medication. Overall, awareness involves a deep understanding and perception of oneself and one's environment.

Insulin lispro is a rapid-acting insulin analog used to treat diabetes mellitus. It is a synthetic version of human insulin in which the amino acid sequence of the insulin molecule has been modified to more closely resemble the natural insulin that is produced by the body. Specifically, the positions of lysine and proline at positions 28 and 29 have been reversed (hence the name "lispro").

This modification results in a faster onset of action and a shorter duration of activity compared to regular human insulin. Insulin lispro typically begins working within 15 minutes after injection, peaks in about an hour, and continues to work for 2-4 hours. It is often used in combination with longer-acting insulins or other medications to help control blood sugar levels throughout the day.

Insulin lispro is available under the brand names Humalog and Admelog, among others. It is administered by injection under the skin (subcutaneously) using a syringe or an insulin pen. As with all insulins, it should be used with caution and under the guidance of a healthcare provider to minimize the risk of hypoglycemia (low blood sugar) and other potential side effects.

Ambulatory monitoring is a medical practice that involves the continuous or intermittent recording of physiological parameters in a patient who is mobile and able to perform their usual activities while outside of a hospital or clinical setting. This type of monitoring allows healthcare professionals to evaluate a patient's condition over an extended period, typically 24 hours or more, in their natural environment.

Ambulatory monitoring can be used to diagnose and manage various medical conditions such as hypertension, cardiac arrhythmias, sleep disorders, and mobility issues. Common methods of ambulatory monitoring include:

1. Holter monitoring: A small, portable device that records the electrical activity of the heart for 24-48 hours or more.
2. Ambulatory blood pressure monitoring (ABPM): A device that measures blood pressure at regular intervals throughout the day and night.
3. Event monitors: Devices that record heart rhythms only when symptoms occur or when activated by the patient.
4. Actigraphy: A non-invasive method of monitoring sleep-wake patterns, physical activity, and circadian rhythms using a wristwatch-like device.
5. Continuous glucose monitoring (CGM): A device that measures blood sugar levels continuously throughout the day and night.

Overall, ambulatory monitoring provides valuable information about a patient's physiological status in their natural environment, allowing healthcare professionals to make informed decisions regarding diagnosis, treatment, and management of medical conditions.

Insulin aspart is a rapid-acting insulin analog used to treat diabetes mellitus. It is structurally modified from human insulin by replacing the amino acid proline with aspartic acid at position B28. This modification allows insulin aspart to have a faster onset and shorter duration of action compared to regular human insulin, making it suitable for mealtime dosing. Insulin aspart is usually administered subcutaneously and starts to lower blood glucose levels within 10-20 minutes after injection, peaking around 1-3 hours, and its effect lasts for approximately 3-5 hours. It is available under the brand name Novolog or Fiasp (a newer formulation with faster absorption).

Isophane Insulin, also known as NPH (Neutral Protamine Hagedorn) Insulin, is an intermediate-acting insulin preparation that combines insulin with protamine to form a suspension that provides a relatively consistent and prolonged duration of action. It starts to lower blood glucose levels within 2-4 hours after injection, peaks around 4-10 hours, and continues to work for up to 18-20 hours. This makes it suitable for use in basal insulin regimens to cover the body's needs for insulin between meals and during the night.

Diazoxide is a medication that is primarily used to treat hypoglycemia (low blood sugar) in newborns and infants. It works by inhibiting the release of insulin from the pancreas, which helps to prevent the blood sugar levels from dropping too low. Diazoxide may also be used in adults with certain rare conditions that cause hypoglycemia.

In addition to its use as a hypoglycemic agent, diazoxide has been used off-label for other indications, such as the treatment of hypertension (high blood pressure) that is resistant to other medications. It works as a vasodilator, relaxing the smooth muscle in the walls of blood vessels and causing them to widen, which reduces the resistance to blood flow and lowers blood pressure.

Diazoxide is available as an injection and is typically administered in a hospital setting under the close supervision of a healthcare professional. Common side effects of diazoxide include fluid retention, headache, nausea, and vomiting. It may also cause rare but serious side effects such as heart rhythm disturbances and allergic reactions.

"Regular Insulin, Pork" is a type of insulin that is derived from the pancreas of pigs. It is a short-acting insulin, which means it starts to lower blood sugar within 30 minutes after injection and its effect peaks around 2-3 hours after injection, and continues to work for approximately 3-6 hours. Regular Insulin, Pork is used to control the level of glucose (sugar) in the blood of people with diabetes mellitus. It is administered subcutaneously (under the skin), and its effects are similar to those of human insulin. However, it may cause a stronger immune reaction and more frequent allergic reactions compared to human insulin.

Gluconeogenesis is a metabolic pathway that occurs in the liver, kidneys, and to a lesser extent in the small intestine. It involves the synthesis of glucose from non-carbohydrate precursors such as lactate, pyruvate, glycerol, and certain amino acids. This process becomes particularly important during periods of fasting or starvation when glucose levels in the body begin to drop, and there is limited carbohydrate intake to replenish them.

Gluconeogenesis helps maintain blood glucose homeostasis by providing an alternative source of glucose for use by various tissues, especially the brain, which relies heavily on glucose as its primary energy source. It is a complex process that involves several enzymatic steps, many of which are regulated to ensure an adequate supply of glucose while preventing excessive production, which could lead to hyperglycemia.

3-Hydroxybutyric acid, also known as β-hydroxybutyric acid, is a type of ketone body that is produced in the liver during the metabolism of fatty acids. It is a colorless, slightly water-soluble compound with a bitter taste and an unpleasant odor.

In the body, 3-hydroxybutyric acid is produced when there is not enough glucose available to meet the body's energy needs, such as during fasting, starvation, or prolonged intense exercise. It can also be produced in large amounts in people with uncontrolled diabetes, particularly during a condition called diabetic ketoacidosis.

3-Hydroxybutyric acid is an important source of energy for the brain and other organs during periods of low glucose availability. However, high levels of 3-hydroxybutyric acid in the blood can lead to a condition called ketosis, which can cause symptoms such as nausea, vomiting, abdominal pain, and confusion. If left untreated, ketosis can progress to diabetic ketoacidosis, a potentially life-threatening complication of diabetes.

The Autonomic Nervous System (ANS) is a part of the peripheral nervous system that operates largely below the level of consciousness and controls visceral functions. It is divided into two main subdivisions: the sympathetic and parasympathetic nervous systems, which generally have opposing effects and maintain homeostasis in the body.

The Sympathetic Nervous System (SNS) prepares the body for stressful or emergency situations, often referred to as the "fight or flight" response. It increases heart rate, blood pressure, respiratory rate, and metabolic rate, while also decreasing digestive activity. This response helps the body respond quickly to perceived threats.

The Parasympathetic Nervous System (PNS), on the other hand, promotes the "rest and digest" state, allowing the body to conserve energy and restore itself after the stress response has subsided. It decreases heart rate, blood pressure, and respiratory rate, while increasing digestive activity and promoting relaxation.

These two systems work together to maintain balance in the body by adjusting various functions based on internal and external demands. Disorders of the Autonomic Nervous System can lead to a variety of symptoms, such as orthostatic hypotension, gastroparesis, and cardiac arrhythmias, among others.

Subcutaneous infusion is a method of administering medication or fluids into the body through the layer of skin and tissue beneath the dermis and above the muscle. This is typically done using an infusion pump that delivers the medication or fluid in small, continuous amounts. The medication or fluid is usually contained in a sterile bag or bottle and is connected to the infusion pump via a tube with a needle at the end. The needle is inserted through the skin into the subcutaneous tissue, allowing the medication or fluid to be slowly infused into the body.

Subcutaneous infusions are often used to administer medications that need to be given over a long period of time, such as antibiotics, pain relievers, and immunosuppressive drugs. They can also be used to provide fluids and electrolytes to patients who are unable to drink or eat enough on their own. Subcutaneous infusions are generally well-tolerated and have fewer complications than intravenous (IV) infusions, making them a good option for many patients. However, they may not be suitable for all medications or for patients with certain medical conditions. It is important to consult with a healthcare provider to determine the most appropriate method of administration for a given medication or treatment.

Human Growth Hormone (HGH), also known as somatotropin, is a peptide hormone produced in the pituitary gland. It plays a crucial role in human development and growth by stimulating the production of another hormone called insulin-like growth factor 1 (IGF-1). IGF-1 promotes the growth and reproduction of cells throughout the body, particularly in bones and other tissues. HGH also helps regulate body composition, body fluids, muscle and bone growth, sugar and fat metabolism, and possibly heart function. It is essential for human development and continues to have important effects throughout life. The secretion of HGH decreases with age, which is thought to contribute to the aging process.

An islet cell adenoma is a rare, typically benign tumor that develops in the islets of Langerhans, which are clusters of hormone-producing cells in the pancreas. The islets of Langerhans contain several types of cells, including beta cells that produce insulin, alpha cells that produce glucagon, and delta cells that produce somatostatin.

Islet cell adenomas can cause various endocrine disorders depending on the type of hormone-producing cells involved. For example, if the tumor consists mainly of beta cells, it may secrete excessive amounts of insulin, leading to hypoglycemia (low blood sugar). Conversely, if the tumor is composed primarily of alpha cells, it may produce too much glucagon, resulting in hyperglycemia (high blood sugar) and a condition known as glucagonoma.

Islet cell adenomas are usually slow-growing and small but can become quite large in some cases. They are typically diagnosed through imaging tests such as CT scans or MRI, and hormone levels may be measured to determine the type of cells involved. Treatment options include surgical removal of the tumor, medication to manage hormonal imbalances, and, in rare cases, radiofrequency ablation or embolization.

Pure Autonomic Failure (PAF) is a rare neurological disorder characterized by the progressive loss of function of the autonomic nervous system, which regulates involuntary bodily functions such as heart rate, blood pressure, sweating, digestion, and bladder control. In PAF, there is no evidence of any other underlying disease or neurological condition that could explain these symptoms.

The primary feature of PAF is orthostatic hypotension, a sudden drop in blood pressure when standing up from a sitting or lying down position, which can lead to dizziness, lightheadedness, and even fainting. Other common symptoms include:

* Anhidrosis (inability to sweat) or hyperhidrosis (excessive sweating)
* Constipation or diarrhea
* Urinary incontinence or retention
* Sexual dysfunction
* Tachycardia (rapid heart rate) or bradycardia (slow heart rate)
* Difficulty regulating body temperature

The exact cause of PAF is unknown, but it is believed to be related to the degeneration of nerve cells in the autonomic nervous system. There is no cure for PAF, and treatment is focused on managing symptoms and preventing complications. This may include lifestyle changes such as increasing fluid and salt intake, wearing compression stockings, and avoiding prolonged periods of standing or sitting. Medications may also be prescribed to help regulate blood pressure, heart rate, and other autonomic functions.

Homeostasis is a fundamental concept in the field of medicine and physiology, referring to the body's ability to maintain a stable internal environment, despite changes in external conditions. It is the process by which biological systems regulate their internal environment to remain in a state of dynamic equilibrium. This is achieved through various feedback mechanisms that involve sensors, control centers, and effectors, working together to detect, interpret, and respond to disturbances in the system.

For example, the body maintains homeostasis through mechanisms such as temperature regulation (through sweating or shivering), fluid balance (through kidney function and thirst), and blood glucose levels (through insulin and glucagon secretion). When homeostasis is disrupted, it can lead to disease or dysfunction in the body.

In summary, homeostasis is the maintenance of a stable internal environment within biological systems, through various regulatory mechanisms that respond to changes in external conditions.

Diabetes Mellitus is a chronic metabolic disorder characterized by elevated levels of glucose in the blood (hyperglycemia) due to absolute or relative deficiency in insulin secretion and/or insulin action. There are two main types: Type 1 diabetes, which results from the autoimmune destruction of pancreatic beta cells leading to insulin deficiency, and Type 2 diabetes, which is associated with insulin resistance and relative insulin deficiency.

Type 1 diabetes typically presents in childhood or young adulthood, while Type 2 diabetes tends to occur later in life, often in association with obesity and physical inactivity. Both types of diabetes can lead to long-term complications such as damage to the eyes, kidneys, nerves, and cardiovascular system if left untreated or not well controlled.

The diagnosis of diabetes is usually made based on fasting plasma glucose levels, oral glucose tolerance tests, or hemoglobin A1c (HbA1c) levels. Treatment typically involves lifestyle modifications such as diet and exercise, along with medications to lower blood glucose levels and manage associated conditions.

Dumping syndrome, also known as rapid gastric emptying, is a condition that typically occurs in people who have had surgery to remove all or part of their stomach (gastrectomy) or have had a procedure called a gastrojejunostomy. These surgeries can lead to the stomach's contents entering the small intestine too quickly, causing symptoms such as nausea, vomiting, abdominal cramping, diarrhea, dizziness, and sweating.

There are two types of dumping syndrome: early and late. Early dumping syndrome occurs within 30 minutes after eating, while late dumping syndrome occurs 1-3 hours after eating. Symptoms of early dumping syndrome may include nausea, vomiting, abdominal cramping, diarrhea, bloating, dizziness, and fatigue. Late dumping syndrome symptoms may include hypoglycemia (low blood sugar), which can cause sweating, weakness, confusion, and rapid heartbeat.

Treatment for dumping syndrome typically involves dietary modifications, such as eating smaller, more frequent meals that are low in simple sugars, and avoiding fluids during meals. In some cases, medication may be prescribed to help slow down gastric emptying or manage symptoms. If these treatments are not effective, surgery may be necessary to correct the problem.

Fasting is defined in medical terms as the abstinence from food or drink for a period of time. This practice is often recommended before certain medical tests or procedures, as it helps to ensure that the results are not affected by recent eating or drinking.

In some cases, fasting may also be used as a therapeutic intervention, such as in the management of seizures or other neurological conditions. Fasting can help to lower blood sugar and insulin levels, which can have a variety of health benefits. However, it is important to note that prolonged fasting can also have negative effects on the body, including malnutrition, dehydration, and electrolyte imbalances.

Fasting is also a spiritual practice in many religions, including Christianity, Islam, Buddhism, and Hinduism. In these contexts, fasting is often seen as a way to purify the mind and body, to focus on spiritual practices, or to express devotion or mourning.

A pancreatectomy is a surgical procedure in which all or part of the pancreas is removed. There are several types of pancreatectomies, including:

* **Total pancreatectomy:** Removal of the entire pancreas, as well as the spleen and nearby lymph nodes. This type of pancreatectomy is usually done for patients with cancer that has spread throughout the pancreas or for those who have had multiple surgeries to remove pancreatic tumors.
* **Distal pancreatectomy:** Removal of the body and tail of the pancreas, as well as nearby lymph nodes. This type of pancreatectomy is often done for patients with tumors in the body or tail of the pancreas.
* **Partial (or segmental) pancreatectomy:** Removal of a portion of the head or body of the pancreas, as well as nearby lymph nodes. This type of pancreatectomy is often done for patients with tumors in the head or body of the pancreas that can be removed without removing the entire organ.
* **Pylorus-preserving pancreaticoduodenectomy (PPPD):** A type of surgery used to treat tumors in the head of the pancreas, as well as other conditions such as chronic pancreatitis. In this procedure, the head of the pancreas, duodenum, gallbladder, and bile duct are removed, but the stomach and lower portion of the esophagus (pylorus) are left in place.

After a pancreatectomy, patients may experience problems with digestion and blood sugar regulation, as the pancreas plays an important role in these functions. Patients may need to take enzyme supplements to help with digestion and may require insulin therapy to manage their blood sugar levels.

Nonesterified fatty acids (NEFA), also known as free fatty acids (FFA), refer to fatty acid molecules that are not bound to glycerol in the form of triglycerides or other esters. In the bloodstream, NEFAs are transported while bound to albumin and can serve as a source of energy for peripheral tissues. Under normal physiological conditions, NEFA levels are tightly regulated by the body; however, elevated NEFA levels have been associated with various metabolic disorders such as insulin resistance, obesity, and type 2 diabetes.

Adrenocorticotropic Hormone (ACTH) is a hormone produced and released by the anterior pituitary gland, a small endocrine gland located at the base of the brain. ACTH plays a crucial role in the regulation of the body's stress response and has significant effects on various physiological processes.

The primary function of ACTH is to stimulate the adrenal glands, which are triangular-shaped glands situated on top of the kidneys. The adrenal glands consist of two parts: the outer cortex and the inner medulla. ACTH specifically targets the adrenal cortex, where it binds to specific receptors and initiates a series of biochemical reactions leading to the production and release of steroid hormones, primarily cortisol (a glucocorticoid) and aldosterone (a mineralocorticoid).

Cortisol is involved in various metabolic processes, such as regulating blood sugar levels, modulating the immune response, and helping the body respond to stress. Aldosterone plays a vital role in maintaining electrolyte and fluid balance by promoting sodium reabsorption and potassium excretion in the kidneys.

ACTH release is controlled by the hypothalamus, another part of the brain, which produces corticotropin-releasing hormone (CRH). CRH stimulates the anterior pituitary gland to secrete ACTH, which in turn triggers cortisol production in the adrenal glands. This complex feedback system helps maintain homeostasis and ensures that appropriate amounts of cortisol are released in response to various physiological and psychological stressors.

Disorders related to ACTH can lead to hormonal imbalances, resulting in conditions such as Cushing's syndrome (excessive cortisol production) or Addison's disease (insufficient cortisol production). Proper diagnosis and management of these disorders typically involve assessing the function of the hypothalamic-pituitary-adrenal axis and addressing any underlying issues affecting ACTH secretion.

A newborn infant is a baby who is within the first 28 days of life. This period is also referred to as the neonatal period. Newborns require specialized care and attention due to their immature bodily systems and increased vulnerability to various health issues. They are closely monitored for signs of well-being, growth, and development during this critical time.

Sulfonylurea receptors (SURs) are a type of transmembrane protein found in the beta cells of the pancreas. They are part of the ATP-sensitive potassium (KATP) channel complex, which plays a crucial role in regulating insulin secretion.

SURs have two subtypes, SUR1 and SUR2, which are associated with different KATP channel subunits. SUR1 is primarily found in the pancreas and brain, while SUR2 is expressed in various tissues, including skeletal muscle and heart.

Sulfonylurea drugs, used to treat type 2 diabetes, bind to SURs and stimulate insulin secretion by closing the KATP channel, which leads to membrane depolarization and subsequent calcium influx, triggering insulin release from beta cells.

Factitious disorders are a group of mental health conditions in which a person deliberately acts as if they have a physical or mental illness when they are not actually experiencing the symptoms. This is also sometimes referred to as "Munchausen syndrome" or "Munchausen by proxy" when it involves caregivers exaggerating, fabricating, or inducing symptoms in another person, typically a child.

People with factitious disorders may go to great lengths to deceive others, including healthcare professionals, and may undergo unnecessary medical treatments, surgeries, or take medications that can cause them harm. The motivation behind this behavior is often a complex mix of factors, including the need for attention, control, or a desire to escape from difficult situations.

It's important to note that factitious disorders are different from malingering, which is the deliberate feigning or exaggeration of symptoms for external incentives such as financial gain, avoiding work or military duty, or obtaining drugs. Factitious disorders, on the other hand, are driven by internal motivations and can cause significant distress and impairment in a person's life.

Dipeptidyl-Peptidase IV (DPP-4) inhibitors are a class of medications used to treat type 2 diabetes. They work by increasing the levels of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), which help regulate blood sugar levels in the body.

Incretin hormones are released from the gut in response to food intake and promote insulin secretion, suppress glucagon secretion, slow down gastric emptying, and reduce appetite. However, these hormones are rapidly degraded by the enzyme DPP-4, which reduces their effectiveness.

DPP-4 inhibitors block the action of this enzyme, thereby increasing the levels of incretin hormones in the body and enhancing their effects on blood sugar control. Some examples of DPP-4 inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin.

These medications are usually taken orally once or twice a day and are often used in combination with other diabetes medications, such as metformin or sulfonylureas, to achieve better blood sugar control. Common side effects of DPP-4 inhibitors include upper respiratory tract infections, headache, and nasopharyngitis (inflammation of the throat and nasal passages).

Metformin is a type of biguanide antihyperglycemic agent used primarily in the treatment of type 2 diabetes mellitus. It works by decreasing glucose production in the liver, reducing glucose absorption in the gut, and increasing insulin sensitivity in muscle and fat tissue. By lowering both basal and postprandial plasma glucose levels, metformin helps to control blood sugar levels and improve glycemic control. It is also used off-label for various other indications such as polycystic ovary syndrome (PCOS) and gestational diabetes. Common side effects include diarrhea, nausea, vomiting, and abdominal discomfort. Lactic acidosis is a rare but serious side effect that requires immediate medical attention.

The Islets of Langerhans are clusters of specialized cells within the pancreas, an organ located behind the stomach. These islets are named after Paul Langerhans, who first identified them in 1869. They constitute around 1-2% of the total mass of the pancreas and are distributed throughout its substance.

The Islets of Langerhans contain several types of cells, including:

1. Alpha (α) cells: These produce and release glucagon, a hormone that helps to regulate blood sugar levels by promoting the conversion of glycogen to glucose in the liver when blood sugar levels are low.
2. Beta (β) cells: These produce and release insulin, a hormone that promotes the uptake and utilization of glucose by cells throughout the body, thereby lowering blood sugar levels.
3. Delta (δ) cells: These produce and release somatostatin, a hormone that inhibits the release of both insulin and glucagon and helps regulate their secretion in response to changing blood sugar levels.
4. PP cells (gamma or Îł cells): These produce and release pancreatic polypeptide, which plays a role in regulating digestive enzyme secretion and gastrointestinal motility.

Dysfunction of the Islets of Langerhans can lead to various endocrine disorders, such as diabetes mellitus, where insulin-producing beta cells are damaged or destroyed, leading to impaired blood sugar regulation.

A "newborn infant" refers to a baby in the first 28 days of life outside of the womb. This period is crucial for growth and development, but also poses unique challenges as the infant's immune system is not fully developed, making them more susceptible to various diseases.

"Newborn diseases" are health conditions that specifically affect newborn infants. These can be categorized into three main types:

1. Congenital disorders: These are conditions that are present at birth and may be inherited or caused by factors such as infection, exposure to harmful substances during pregnancy, or chromosomal abnormalities. Examples include Down syndrome, congenital heart defects, and spina bifida.

2. Infectious diseases: Newborn infants are particularly vulnerable to infections due to their immature immune systems. Common infectious diseases in newborns include sepsis (bloodstream infection), pneumonia, and meningitis. These can be acquired from the mother during pregnancy or childbirth, or from the environment after birth.

3. Developmental disorders: These are conditions that affect the normal growth and development of the newborn infant. Examples include cerebral palsy, intellectual disabilities, and vision or hearing impairments.

It is important to note that many newborn diseases can be prevented or treated with appropriate medical care, including prenatal care, proper hygiene practices, and timely vaccinations. Regular check-ups and monitoring of the newborn's health by a healthcare provider are essential for early detection and management of any potential health issues.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

The word hypoglycemia is also spelled hypoglycaemia or hypoglycæmia. The term means 'low blood sugar' from Greek ὑπογλυκαιμία, ... Some causes of hypoglycemia require treatment of the underlying cause to best prevent hypoglycemia. This is the case for ... Hypoglycemia is most common in those with diabetes treated by insulin, glinides, and sulfonylureas. Hypoglycemia is rare in ... Recurrent episodes of hypoglycemia can lead to hypoglycemic unawareness, or the decreased ability to recognize hypoglycemia. As ...
... can also be a synonym for reactive hypoglycemia or for hypoglycemia that is not diagnosed by a ... Idiopathic hypoglycemia is a medical condition in which the glucose level in the blood (blood glucose) is abnormally low due to ... In general, the more severe the hypoglycemia and the more clearly it is proven, the less likely it is to remain "idiopathic". ... Hyperinsulinism Perry, Julian C.; Bourne, Blanche; Lester Henry, W. (January 1957). "Idiopathic Hypoglycemia in Childhood: ...
It remains one of the more common causes of hypoglycemia in the age range. The typical patient with ketotic hypoglycemia is a ... Absence of ketosis ("nonketotic hypoglycemia") most often indicates excessive insulin as the cause of the hypoglycemia. Less ... Ketotic hypoglycemia is a medical term used in two ways: (1) broadly, to refer to any circumstance in which low blood glucose ... A high level of ketones in the blood, ketosis, is thus a normal response to hypoglycemia in healthy people of all ages.[ ...
... , postprandial hypoglycemia, or sugar crash is a term describing recurrent episodes of symptomatic ... It is recommended that the term reactive hypoglycemia be reserved for the pattern of postprandial hypoglycemia which meets the ... "Reactive Hypoglycemia". Mayo Foundation for Medical Education and Research. Retrieved November 11, 2011. "Hypoglycemia (Low ... Along with the symptoms of hypoglycemia, symptoms of reactive hypoglycemia include: double vision or blurry vision unclear ...
Of all the hypoglycemia symptoms, sweating is typically not blocked by beta blockers. Diabetes alert dog Diabetic Hypoglycemia ... "hypoglycemia [TUSOM , Pharmwiki]". tmedweb.tulane.edu. Diabetic Hypoglycemia website Diabetes In Control-Drugs that may affect ... Symptoms of diabetic hypoglycemia, when they occur, are those of hypoglycemia: neuroglycopenic, adrenergic (that is, activating ... A common medical definition of severe hypoglycemia is "hypoglycemia severe enough that the person needs assistance in dealing ...
Hypoglycemia due to excess insulin is the most common type of serious hypoglycemia. It can be due to endogenous or injected ... Manifestations of hyperinsulinemic hypoglycemia vary by age and severity of the hypoglycemia. In general, most signs and ... Reversal and prevention of hypoglycemia is a major aspect of the management of type 1 diabetes. Hypoglycemia due to drug ... Death or permanent brain damage resembling stroke can occur rarely as a result of severe hypoglycemia. See hypoglycemia for ...
"Neonatal Hypoglycemia". Medscape. "Identification and Management of Neonatal Hypoglycaemia in the Full Term Infant - A ... In the US, hypoglycemia is when the blood glucose level is below 30 mg/dL within the first 24 hours of life and below 45 mg/dL ... Neonatal hypoglycemia occurs when the neonate's blood glucose level is less than the newborn's body requirements for factors ... Any infant at risk of hypoglycemia should have their blood sugar taken again one hour after birth. Oral glucose is another ...
Diabetic Hypoglycemia is a triannual open access peer-reviewed medical journal published by ESP Bioscience. It publishes review ... topical review on a particular area of diabetes and diabetic hypoglycemia treatment, with commentary by a member of the ... and clinical aspects of hypoglycemia prevention, diagnosis and management. The journal was established in 2008, with the ... round-up of abstracts from a recent major congress or meeting and of recent publications relating to diabetic hypoglycemia, ...
... is a condition in which a tumor secretes hormones into the bloodstream that cause ... hypoglycemia. The is most commonly insulin-like growth factor 2, which stimulates insulin receptors to uptake glucose into ...
Other names include hypoglycemia leucine-induced; hypoglycemia leucine induced; and familial infantile hypoglycemia ... "OMIM Entry - # 240800 - HYPOGLYCEMIA, LEUCINE-INDUCED; LIH". www.omim.org. Retrieved 27 October 2019. "Hypoglycemia, Leucine- ... Leucine-sensitive hypoglycemia of infancy is a type of metabolic disorder. It is inherited in an autosomal dominant fashion. It ... "Leucine-sensitive hypoglycemia of infancy , Genetic and Rare Diseases Information Center (GARD) - an NCATS Program". ...
Recurrent mild hypoglycemia may fit a reactive hypoglycemia pattern, but this is also the peak age for idiopathic postprandial ... The following is a list of causes of hypoglycemia Hypoglycemia is a common problem with an increasing incidence in critically ... Body mass is large enough to make starvation hypoglycemia and idiopathic ketotic hypoglycemia quite uncommon. ... hyperinsulinemic hypoglycemia type 3 Familial hyperinsulinemic hypoglycemia type 5 Familial hyperinsulinemic hypoglycemia type ...
The primary adverse effect of any insulin product is hypoglycemia, or low blood sugar. Hypoglycemia can manifest as dizziness, ... In severe cases, hypoglycemia can lead to loss of consciousness if not treated. As lente insulin continues to be absorbed in ... "Hypoglycemia". National Institute of Diabetes and Digestive and Kidney Diseases. October 2008. Archived from the original on 1 ...
The primary adverse effect of any insulin product is hypoglycemia, or low blood sugar. Hypoglycemia can manifest as dizziness, ... In severe cases, hypoglycemia can lead to loss of consciousness if not treated. As lente insulin continues to be absorbed in ... "Hypoglycemia". National Institute of Diabetes and Digestive and Kidney Diseases. October 2008. Archived from the original on 1 ... making for more predictable effects and less risk of hypoglycemia. After the discontinuation of lente insulin for human use, ...
Hypoglycemia, also known as "low blood sugar", is when blood sugar decreases to below normal levels. This may result in a ... "Hypoglycemia". National Institute of Diabetes and Digestive and Kidney Diseases. October 2008. Archived from the original on 1 ... Other causes of hypoglycemia include kidney failure, certain tumors, such as insulinoma, liver disease, hypothyroidism, ... The most common cause of hypoglycemia is medications used to treat diabetes mellitus such as insulin and sulfonylureas. Risk is ...
Hypoglycemia is a fall in blood sugar to levels below normal. This may result in a variety of symptoms including clumsiness, ... "Hypoglycemia". National Institute of Diabetes and Digestive and Kidney Diseases. October 2008. Archived from the original on 1 ... They include hyperglycemia, hypoglycemia, impaired glucose tolerance test, impaired fasting glucose, among others. If blood ... Other causes of hypoglycemia include kidney failure, certain tumors (such as insulinoma), liver disease, hypothyroidism, ...
Hypoglycaemia and dehydration seem to go hand-in-hand, and force-feeding or injecting fluids may also be necessary. ... Hypoglycaemia causes the puppy to become drowsy, listless (glassy-eyed), shaky, uncpoglycaemic attack, the puppy usually has ... "Hypoglycemia". Pomeranian Club of Canada. Retrieved 10 March 2007. "FCI-Standard". Archived from the original on 31 August 2012 ... "Hypoglycemia symptoms and treatment". Go Pets America. Retrieved 10 March 2007. O'Neil, Jacqueline (2007). "Dealing with Your ...
November 1 Diana Victoria González Barrera, 26, soccer player with Club América; hypoglycemia. Rina Lazo, 93, muralist (Fertile ...
"Nighttime Hypoglycemia". Diabetes Self Management. 9 April 2014. Beccuti G, Monagheddu C, Evangelista A, Ciccone G, Broglio F, ... Consumption of alcohol also puts diabetics at increased risk of hypoglycemia. The ADA states that this may be due to the " ... Consuming food with alcohol reduces this risk of hypoglycemia. There has been a long history of dietary treatment of diabetes ... Another possible sign of nocturnal hypoglycemia is morning hyperglycemia, which actually occurs in response to blood sugar ...
... causing hypoglycemia. Usual presenting features are multiple episodes of spontaneous hypoglycemia and appearance of insulin ... Y., Hirata (1970). "Insulin autoimmunity in a case of spontaneous hypoglycemia". J Jpn Diabet Soc. 13: 312-319. JB, Redmon; FQ ... Insulin autoimmune syndrome (IAS), a rare cause of reversible autoimmune hypoglycemia also known as Hirata's disease, was first ... BC, Lupsa; AY, Chong; EK, Cochran; MA, Soos; RK, Semple; P, Gorden (2009). "Autoimmune forms of hypoglycemia". Medicine ( ...
Hypoglycemia a condition in which blood glucose levels are lower than normal. This can be caused by an overdose of insulin (too ... See also: Hypoglycemia; insulin reaction. Insulinoma A tumor of the beta cells in areas of the pancreas called the islets of ... See also: Hypoglycemia; insulin shock. Insulin receptors Protein complexes on the surface of a cell that allows the cell to ... Also called "rebound hypoglycemia". Sorbitol a kind of combination alcohol-sugar. A member of the polyol class of chemicals. ...
... also known as hypoglycemia. Hypoglycemia is accompanied by many of the above listed neuroglycopenic and/or autonomic symptoms. ... Therefore, resolving hypoglycemia.[citation needed] The prognosis once diagnosed with metastatic insulinoma falls on a large ... After the initial presentation of hypoglycemic symptoms, blood tests are taken in order to confirm hypoglycemia. A glucose, ... Iglesias P, DĂ­ez JJ (April 2014). "Management of endocrine disease: a clinical update on tumor-induced hypoglycemia". European ...
Hypoglycemia may be present. This is termed a salt-wasting crisis and rapidly causes death if not treated.[medical citation ...
"Hypoglycemia (Low Blood Glucose)". diabetes.org. American Diabetes Association. Archived from the original on 24 June 2010. ... Also known as insulin shock, hypoglycemia can lead to coma or even death. In current research, the significant relationship ...
"Hypoglycemia (Low Blood sugar)". American Diabetes Association. 2021. Retrieved December 12, 2021. Shane III, Leo (July 14, ... hospital staff eventually attributed the deaths of several patients on the ward to hypoglycemia. Many of the deaths were of ...
Hyperinsulinemic hypoglycemia, familial, 7 (HHF7) is an autosomal dominant disease on the SLC16A1/MCT gene on chromosome 1p13.2 ... It causes hyperinsulinemic hypoglycemia, where hyperinsulinism is exercise-induced. Monocarboxylate transporter 1 deficiency ( ... "HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 7; HHF7". omim.org. Retrieved 2023-08-21. "MONOCARBOXYLATE TRANSPORTER 1 DEFICIENCY; ... It causes poor feeding and vomiting, intellectual disability, ketotic hypoglycemia, ketoacidosis, ketonuria, with episodes ...
"Diabetic Hypoglycemia Online Journal Editorial Board: Prevention, Diagnosis & Management of Hypoglycemia in Diabetes". www. ... "Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia". Diabetes Care. 17 ( ... Hypoglycaemia in clinical diabetes. Brian M. Frier, Simon R. Heller, Rory J. McCrimmon. Chichester, West Sussex, UK. 2014. ISBN ... "Hypoglycemia Expert Meeting" (PDF). ihsgonline.com. Archived (PDF) from the original on 23 April 2021. "5 Years of Innovative ...
Hypoglycemia, as well as hyperbilirubinemia and polycythemia, occurs as a result of hyperinsulinemia in the fetus. High birth ... LGA babies are at higher risk of hypoglycemia in the neonatal period, independent of whether the mother has diabetes. ... Rozance PJ (February 2014). "Update on neonatal hypoglycemia". Current Opinion in Endocrinology, Diabetes and Obesity. 21 (1): ... Common risks in LGA babies include shoulder dystocia, hypoglycemia, brachial plexus injuries, metatarsus adductus, hip ...
Goodwin, Matthew L.; Gladden, L. Bruce; Nijsten, Maarten W. N. (2020-09-03). "Lactate-Protected Hypoglycemia (LPH)". Frontiers ... values below 40 mg/dL are termed hypoglycaemia. When needed, glucose is released into the bloodstream by glucose-6-phosphatase ... containing lactic acid and insulin intended to induce hypoglycemia and hyperlactatemia to combat different cancers and ...
Fetal - tachycardia and hypoglycemia. The tertiary butyl group in terbutaline makes it more selective for β2 receptors. Since ...
Ingestion may cause hypoglycemia. Avocado leaves, bark, skin, and pit are known to be harmful to a wide range of animals, ... Dunayer EK (April 2004). "Hypoglycemia following canine ingestion of xylitol-containing gum". Vet. Hum. Toxicol. 46 (2): 87-8. ...
The word hypoglycemia is also spelled hypoglycaemia or hypoglycæmia. The term means low blood sugar from Greek ὑπογλυκαιμία, ... Some causes of hypoglycemia require treatment of the underlying cause to best prevent hypoglycemia. This is the case for ... Hypoglycemia is most common in those with diabetes treated by insulin, glinides, and sulfonylureas. Hypoglycemia is rare in ... Recurrent episodes of hypoglycemia can lead to hypoglycemic unawareness, or the decreased ability to recognize hypoglycemia. As ...
Find out about symptoms and treatment, and how to spot hypoglycemia unawareness. ... Hypoglycemia Unawareness. If youve had low blood sugar without feeling or noticing symptoms (hypoglycemia unawareness), you ... If you meet one or more of the above and you have hypoglycemia unawareness, you may need to check your blood sugar more often ... You may not have any symptoms when your blood sugar is low (hypoglycemia unawareness). If you dont have symptoms, it will be ...
... a person presented to the emergency department with severe hypoglycemia caused by inadvertent sulfonylurea overdose. There have ... Persistent Hypoglycemia Led to the Source In the current case, paramedics treated the patient with D50W, and his blood glucose ... "If the hypoglycemia doesnt persist, the [ED] physician wouldnt consult endocrine.... Is this happening more than we think?" ... A 2004 article reports five cases in which people in San Francisco were "admitted to the hospital for hypoglycemia as a result ...
Hypoglycemia is a clinical situation characterized by a reduction in plasma glucose concentration to a level that may induce ... See also Pediatric Hypoglycemia, Neonatal Hypoglycemia, Emergent Management of Acute Symptoms of Hypoglycemia, and Congenital ... Fasting hypoglycemia. Nesidioblastosis is a rare cause of fasting hypoglycemia in infants and an extremely rare cause in adults ... Causes of hypoglycemia are varied, but it is seen most often in diabetic patients. Hypoglycemia may result from medication ...
... its called hypoglycemia. Very low blood sugar levels can cause severe symptoms that require immediate treatment. ... What Is Hypoglycemia?. When blood glucose levels (called blood sugar levels) drop too low, its called hypoglycemia. For people ... What Causes Hypoglycemia?. Hypoglycemia can happen for different reasons. Anyone with diabetes can get low blood sugar, even ... How Is Hypoglycemia Diagnosed?. The only way to know for sure if someone has low blood sugar is to test their blood. If you ...
The opioid pain-reliever tramadol appears to be associated with an increased risk of hospitalization for hypoglycemia, a ... Although hypoglycemia was uncommon in the study of Fournier et al, the true rate is likely higher because hypoglycemia is ... Commentary: Tramadol and Hypoglycemia, 1 More Thing to Worry About In a related commentary, Lewis S. Nelson, M.D., of New York ... Because hypoglycemia can be life threatening, clinicians should remain vigilant for this potential complication of tramadol use ...
Well explain the causes, symptoms, complications, and treatments of hypoglycemia. ... Hypoglycemia is a condition in which you have an abnormally low blood sugar level. It can cause major health problems in those ... Hypoglycemia.(2018).. http://www.nlm.nih.gov/medlineplus/hypoglycemia.html. *. Hypoglycemia.(n.d.).. http://www.ncbi.nlm.nih. ... Hypoglycemia is most common in people with diabetes. However, a few other conditions - most of them rare - can also cause low ...
Hypoglycemia is the most common metabolic problem in neonates. In children, a blood glucose value of less than 40 mg/dL (2. ... encoded search term (Neonatal Hypoglycemia) and Neonatal Hypoglycemia What to Read Next on Medscape ... High-risk groups who need screening for hypoglycemia in the first hour of life include the following [10, 11] :. * Newborns who ... Neonatal Hypoglycemia Clinical Presentation. Updated: Apr 07, 2022 * Author: Hilarie Cranmer, MD, MPH, FACEP; Chief Editor: ...
Discover the physiological mechanisms behind insulin hypoglycemia and its impact on calcitonin secretion. Explore the role of ... Calcitonin Secretion under Insulin Hypoglycemia () Svetlana Stepanovna Moisa1, Alexander Danilovich Nozdrachev2 1Federal State- ... Moisa, S. and Nozdrachev, A. (2014) Calcitonin Secretion under Insulin Hypoglycemia. Open Journal of Endocrine and Metabolic ... Insulin hypoglycemia didnt expose the increasing secretion of calcitonin in rats under adrenalectomy and pancreatectomy. ...
Wayne J. Katon, Bessie A. Young, Joan Russo, Elizabeth H. B. Lin, Paul Ciechanowski, Evette J. Ludman and Michael R. Von Korff ...
Hypoglycemia, or low blood sugar, can happen when your blood sugar drops below the typical range. Learn the symptoms and how to ... Hypoglycemia is more common. in people with diabetes.. This article will take a closer look at hypoglycemia, as well as the ... Hypoglycemia unawareness. Some people may have low blood sugar without any symptoms. This is called hypoglycemia unawareness. ... Hypoglycemia occurs when your blood sugar drops below 70 milligrams per deciliter (mg/dL). Blood sugar is also known as blood ...
Metabolic syndrome and hypoglycemia are two of the most common disorders that ... ... Metabolic syndrome and hypoglycemia are two of the most common disorders that occur in about 20 to 30% of the population ... Knowing the different hypoglycemia symptoms is vital in the treatment so that it should be addressed immediately. Some of the ... The normal glucose level in the body is 80 to 120 mg/dl and when it goes lower than that, it would result to hypoglycemia. ...
Adult onset hypoglycemia insulinoma extrapancreatic tumors liver disease hypoglycemia of hunting dogs late pregnancy or heavy ... Hypoglycemia possible Q: I have a pekinese skipperke mix breed dog about 5 years old who started having what I think may be ... Hypoglycemia Q: Dear Dr. Richards, Thank you very much for the information on stroke and vestibular syndrome. I have another ... Hypoglycemia in hunting dogs is most commonly associated with dogs that are infrequently hunted and are therefore thought to be ...
Open access peer-reviewed chapter
Learn about hypoglycemia, a condition resulting from low blood sugar. Find causes, symptoms (anxiety, nervousness, sweating, ... What are the symptoms of non-diabetic hypoglycemia?. Symptoms of hypoglycemia typically appear at levels below 60 mg/dL. Some ... What is the medical definition of hypoglycemia?. Hypoglycemia (low blood sugar) is a commonly perceived problem. In actuality, ... Generally, hypoglycemia is defined as a serum glucose level (the amount of sugar or glucose in your blood) below 70 mg/dL. ...
Hypoglycemia. Hypoglycemia is the condition of having low blood sugar. Symptoms of low blood sugar include shakiness, headaches ...
Hypoglycaemia is a frequent adverse effect of treatment of diabetes mellitus with insulin and sulphonylureas. Fear of ... Hypoglycaemia can disrupt many everyday activities such as driving, work performance and leisure pursuits. In addition to ... The consequences of hypoglycaemia are discussed, with particular focus on the cardiovascular and neurological morbidities that ... Prevention of hypoglycaemia is an important part of diabetes mellitus management and strategies include patient education, ...
Hypoglycemia Therapy. For patients on insulin drip:. * If blood glucose drops between 80 to 99 mg/dL decrease IV insulin to ... If blood glucose drops , 80 mg/dL stop IV insulin, follow hypoglycemia protocol located under supportive documents, and contact ... If blood glucose drops , 80 mg/dL stop IV insulin, follow hypoglycemia protocol located under supportive documents, and contact ... Consider resuming IV insulin infusion after hypoglycemia is resolved, per discussion with Supervising Physician. If insulin ...
... in Cats. Hypoglycemia is often referred to as "low blood sugar." When your cats body is deprived of sugar, its ... Hypoglycemia in Cats. Hypoglycemia is often referred to as "low blood sugar." When your cats body is deprived of sugar, its ...
Hypoglycemia is a condition in the elderly in which your blood sugar (glucose) level is lower than the standard range. ... What is hypoglycemia unawareness?. Repeated episodes of hypoglycemia can lead to hypoglycemia unawareness. The body and brain ... What is Hypoglycemia?. Hypoglycemia is a condition in the elderly in which your blood sugar (glucose) level is lower than the ... Hypoglycemia is one of the most common acute complications of the treatment of diabetes in the elderly. Hypoglycemia can be a ...
Yes, new therapies are associated with less hypoglycemia risk, and patients are increasingly using continuous glucose ... monitoring, but episodes of hypoglycemia still occur. Some of these episodes are severe, and patients require assistance for ... Hypoglycemia and fear of an episode can be extremely detrimental to patients quality of life. Hypoglycemia is also linked to ... As outlined in the ADA Standards of Care, patients with an increased risk of level 2 or 3 hypoglycemia should have an active ...
While there is no hypoglycemia diet, these eating changes can ease symptoms. ... Hypoglycemia, or low blood sugar, can happen to anyone, including people without diabetes. ... The type of hypoglycemia that occurs in people without diabetes is referred to as reactive hypoglycemia, and it often occurs ... This type of hypoglycemia doesnt usually require medical attention, according to the Mayo Clinic. If instances of hypoglycemia ...
Non-reactive hypoglycemia (aka fasting hypoglycemia). Fasting hypoglycemia can be brought on by drinking alcohol on an empty ... Two forms of hypoglycemia can affect someone without diabetes:. *Fasting hypoglycemia is often triggered by medications or by ... Reactive hypoglycemia. Reactive (also called postprandial) hypoglycemia happens after a meal when the digested and absorbed ... Hangry? This Is What You Should Eat for Hypoglycemia (aka Low Blood Sugar). Hypoglycemia can happen with or without diabetes. ...
... J Med Econ. 2009;12(4):281-90. doi: 10.3111/ ...
... and treatments for both hyperglycemia and hypoglycemia in this article from Accu-Chek. ... What is hypoglycemia?. Hypoglycemia is another term for low blood sugar or blood glucose lower than 70 mg/dL. ... What you can do about hypoglycemia. If your symptoms of low blood sugar are mild, you can use the 15-15 rule. This is one of ... Hypoglycemia: What they are, and what you can do about them.. Learn about the symptoms, causes, and treatments for ...
... only hypoglycemia is associated with increased risk of developmental delays by the time the children reach preschool. What ... New research from the Netherlands has found that neonatal hypoglycemia (glucose values ,1.7 mmol/L) in this population more ... No consensus exists on a threshold level for hypoglycemia that will lead to brain injury, but the researchers believe that ... Of all the neonatal morbidities that commonly plague moderately preterm-born babies, only hypoglycemia is associated with ...
Glucagon infusions appear to be beneficial for problematic neonatal hypoglycemia of different causes. ... Experience with intravenous glucagon infusions as a treatment for resistant neonatal hypoglycemia Arch Pediatr Adolesc Med. ... The change was unrelated to the cause of the hypoglycemia. The frequency of hypoglycemic episodes was significantly reduced, ... Background: Based on limited anecdotal evidence, glucagon is used for the management of intractable neonatal hypoglycemia ...
advanced glycation end products, cancer, candy, eating junk foods, hypoglycemia, insulin reaction, junk food, metabolic ...
What Is Hypoglycemia?. Content. Lots of people wonder if they have hypoglycemia (pronounced: hy-po-gly-SEE-mee-uh), but the ... Who Gets Hypoglycemia?. Almost all teens who take blood sugar-lowering medicine for diabetes get hypoglycemia from time to time ... What Is Hypoglycemia?. Hypoglycemia happens when a persons blood sugar levels are abnormally low, and its a potentially ... How Is Hypoglycemia Diagnosed?. A doctor who thinks a person might have hypoglycemia will ask about the patients medical ...

No FAQ available that match "hypoglycemia"